Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.
P/E ratio for Alpha Tau Medical Ltd. (DRTS)
P/E ratio as of 2023: -7.14
According to Alpha Tau Medical Ltd.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -7.14. At the end of 2022 the company had a P/E ratio of -5.98.
P/E ratio history for Alpha Tau Medical Ltd. from 2019 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -7.14 |
| 2022 | -5.98 |
| 2021 | -14.59 |
| 2020 | -45.98 |
| 2019 | -80.69 |